Literature DB >> 12399969

More cell death in refractory anemia with excess blasts in transformation than in acute myeloid leukemia.

Y O Huh1, I Jilani, E Estey, F Giles, H Kantarjian, E Freireich, M Albitar.   

Abstract

Refractory anemia with excess blasts in transformation (RAEB-T) is a subgroup of myelodysplastic syndrome (MDS) in which the bone marrow blast count ranges from 20% to 30%. The recently proposed World Health Organization Classification of Hematologic Malignancies eliminated this category from MDS by lowering the blast count cutoff for acute myeloid leukemia (AML) from 30% to 20%. However, MDS is distinguished from AML by a significant increase in apoptosis. To investigate the difference in apoptosis between RAEB-T, AML, and other categories of MDS, we prospectively analyzed fresh bone marrow samples using the Annexin V and mitochondrial potential assays. There was a significantly higher level of apoptosis in RAEB-T than in AML according to both assays, while no significant differences between RAEB-T and other categories of MDS were noted. The data suggest that RAEB-T is more likely to be an advanced stage of MDS and biologically different from AML.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12399969     DOI: 10.1038/sj.leu.2402704

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  7 in total

Review 1.  Recent advances in the diagnosis and classification of myeloid neoplasms--comments on the 2008 WHO classification.

Authors:  C C Yin; L J Medeiros; C E Bueso-Ramos
Journal:  Int J Lab Hematol       Date:  2010-07-07       Impact factor: 2.877

Review 2.  Dysplasia has A differential diagnosis: distinguishing genuine myelodysplastic syndromes (MDS) from mimics, imitators, copycats and impostors.

Authors:  David P Steensma
Journal:  Curr Hematol Malig Rep       Date:  2012-12       Impact factor: 3.952

3.  Integrative analysis of next generation sequencing for small non-coding RNAs and transcriptional regulation in Myelodysplastic Syndromes.

Authors:  Dominik Beck; Steve Ayers; Jianguo Wen; Miriam B Brandl; Tuan D Pham; Paul Webb; Chung-Che Chang; Xiaobo Zhou
Journal:  BMC Med Genomics       Date:  2011-02-23       Impact factor: 3.063

4.  Apoptosis-Related Gene Expression Profiling in Hematopoietic Cell Fractions of MDS Patients.

Authors:  Saskia Mc Langemeijer; Niccolo Mariani; Ruth Knops; Christian Gilissen; Rob Woestenenk; Theo de Witte; Gerwin Huls; Bert A van der Reijden; Joop H Jansen
Journal:  PLoS One       Date:  2016-11-30       Impact factor: 3.240

Review 5.  Acute myeloid leukemia - strategies and challenges for targeting oncogenic Hedgehog/GLI signaling.

Authors:  Fritz Aberger; Evelyn Hutterer; Christina Sternberg; Pedro J Del Burgo; Tanja N Hartmann
Journal:  Cell Commun Signal       Date:  2017-01-25       Impact factor: 5.712

Review 6.  Contribution of Aberrant Toll Like Receptor Signaling to the Pathogenesis of Myelodysplastic Syndromes.

Authors:  Luana Chiquetto Paracatu; Laura G Schuettpelz
Journal:  Front Immunol       Date:  2020-06-17       Impact factor: 7.561

7.  EZH2 mutations are related to low blast percentage in bone marrow and -7/del(7q) in de novo acute myeloid leukemia.

Authors:  Xiuli Wang; Haiping Dai; Qian Wang; Qinrong Wang; Yang Xu; Ying Wang; Aining Sun; Jia Ruan; Suning Chen; Depei Wu
Journal:  PLoS One       Date:  2013-04-17       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.